Literature DB >> 14501020

Calpain inhibitors, a treatment for Alzheimer's disease: position paper.

Fortunato Battaglia1, Fabrizio Trinchese, Shumin Liu, Sean Walter, Ralph A Nixon, Ottavio Arancio.   

Abstract

Calpains modulate processes that govern the function and metabolism of proteins key to the pathogenesis of Alzheimer's disease, including tau and amyloid precursor protein. Because activation of the calpain system might contribute to the impairment of synaptic transmission in Alzheimer's disease, we are currently testing the hypotheses that a treatment with calpain inhibitors might restore normal cognition and synaptic transmission in a transgenic model of Alzheimer's disease, the APP (K670N:M671L)/PS1(M146L) mouse. Findings derived from these studies will provide a novel approach to cognitive enhancement in Alzheimer's disease.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14501020     DOI： 10.1385/JMN:20:3:357

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN： 0895-8696            Impact factor:   2.866


  14 in total

Review 1.  Calpain and caspase: can you tell the difference?

Authors:  K K Wang
Journal:  Trends Neurosci       Date:  2000-01       Impact factor: 13.837

2.  The ultrastructural localization of calcium-activated protease "calpain" in rat brain.

Authors:  L S Perlmutter; R Siman; C Gall; P Seubert; M Baudry; G Lynch
Journal:  Synapse       Date:  1988       Impact factor: 2.562

3.  Increased amyloid-beta42(43) in brains of mice expressing mutant presenilin 1.

Authors:  K Duff; C Eckman; C Zehr; X Yu; C M Prada; J Perez-tur; M Hutton; L Buee; Y Harigaya; D Yager; D Morgan; M N Gordon; L Holcomb; L Refolo; B Zenk; J Hardy; S Younkin
Journal:  Nature       Date:  1996-10-24       Impact factor: 49.962

4.  Active site-directed antibodies identify calpain II as an early-appearing and pervasive component of neurofibrillary pathology in Alzheimer's disease.

Authors:  F Grynspan; W R Griffin; A Cataldo; S Katayama; R A Nixon
Journal:  Brain Res       Date:  1997-07-25       Impact factor: 3.252

Review 5.  A synaptic model of memory: long-term potentiation in the hippocampus.

Authors:  T V Bliss; G L Collingridge
Journal:  Nature       Date:  1993-01-07       Impact factor: 49.962

6.  Brain fodrin: substrate for calpain I, an endogenous calcium-activated protease.

Authors:  R Siman; M Baudry; G Lynch
Journal:  Proc Natl Acad Sci U S A       Date:  1984-06       Impact factor: 11.205

7.  Amyloid beta -peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling.

Authors:  Ottavio V Vitolo; Antonino Sant'Angelo; Vincenzo Costanzo; Fortunato Battaglia; Ottavio Arancio; Michael Shelanski
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-20       Impact factor: 11.205

8.  Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice.

Authors:  K Hsiao; P Chapman; S Nilsen; C Eckman; Y Harigaya; S Younkin; F Yang; G Cole
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

9.  Widespread activation of calcium-activated neutral proteinase (calpain) in the brain in Alzheimer disease: a potential molecular basis for neuronal degeneration.

Authors:  K Saito; J S Elce; J E Hamos; R A Nixon
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

Review 10.  Calcium-activated neutral proteinase (calpain) system in aging and Alzheimer's disease.

Authors:  R A Nixon; K I Saito; F Grynspan; W R Griffin; S Katayama; T Honda; P S Mohan; T B Shea; M Beermann
Journal:  Ann N Y Acad Sci       Date:  1994-12-15       Impact factor: 5.691
View more
  25 in total

1.  Calpain inhibition attenuates angiotensin II-induced abdominal aortic aneurysms and atherosclerosis in low-density lipoprotein receptor-deficient mice.

Authors:  Venkateswaran Subramanian; Haruhito A Uchida; Talha Ijaz; Jessica J Moorleghen; Deborah A Howatt; Anju Balakrishnan
Journal:  J Cardiovasc Pharmacol       Date:  2012-01       Impact factor: 3.105

2.  The ankyrin repeat-rich membrane spanning (ARMS)/Kidins220 scaffold protein is regulated by activity-dependent calpain proteolysis and modulates synaptic plasticity.

Authors:  Synphen H Wu; Juan Carlos Arévalo; Veronika E Neubrand; Hong Zhang; Ottavio Arancio; Moses V Chao
Journal:  J Biol Chem       Date:  2010-10-13       Impact factor: 5.157

3.  Inhibition of the cdk5/MEF2 pathway is involved in the antiapoptotic properties of calpain inhibitors in cerebellar neurons.

Authors:  Ester Verdaguer; Daniel Alvira; Andrés Jiménez; Victor Rimbau; Antoni Camins; Mercè Pallàs
Journal:  Br J Pharmacol       Date:  2005-08       Impact factor: 8.739

4.  Beta-amyloid disrupted synaptic vesicle endocytosis in cultured hippocampal neurons.

Authors:  B L Kelly; A Ferreira
Journal:  Neuroscience       Date:  2007-05-17       Impact factor: 3.590

5.  The novel calpain inhibitor A-705253 potently inhibits oligomeric beta-amyloid-induced dynamin 1 and tau cleavage in hippocampal neurons.

Authors:  Roxana C Sinjoanu; Sara Kleinschmidt; Robert S Bitner; Jorge D Brioni; Achim Moeller; Adriana Ferreira
Journal:  Neurochem Int       Date:  2008-06-12       Impact factor: 3.921

6.  Calpain-mediated degradation of myocyte enhancer factor 2D contributes to excitotoxicity by activation of extrasynaptic N-methyl-D-aspartate receptors.

Authors:  Gengze Wei; Yue Yin; Wenming Li; Haruhiko Bito; Hua She; Zixu Mao
Journal:  J Biol Chem       Date:  2012-01-03       Impact factor: 5.157

7.  Beta-amyloid-induced dynamin 1 depletion in hippocampal neurons. A potential mechanism for early cognitive decline in Alzheimer disease.

Authors:  Brent L Kelly; Robert Vassar; Adriana Ferreira
Journal:  J Biol Chem       Date:  2005-07-07       Impact factor: 5.157

Review 8.  Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant?

Authors:  Andrew F Teich; Ottavio Arancio
Journal:  Biochem J       Date:  2012-09-01       Impact factor: 3.857

9.  Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment.

Authors:  Bing Gong; Ottavio V Vitolo; Fabrizio Trinchese; Shumin Liu; Michael Shelanski; Ottavio Arancio
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

Review 10.  Cell cycle inhibition without disruption of neurogenesis is a strategy for treatment of central nervous system diseases.

Authors:  Da-Zhi Liu; Bradley P Ander; Frank R Sharp
Journal:  Neurobiol Dis       Date:  2009-11-24       Impact factor: 5.996
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.